MedTrace Logo

The Effects of Dexamethasone Administration on Jaundice Following Liver Resection

NCT02991339 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2021-06-10

No results posted yet for this study

Summary

The investigators were aiming to evaluate whether dexamethasone administration accelerates the recovery from hepatectomy-related jaundice and decreases the rates of post-hepatectomy liver failure and its safety in the subjects who developed elevated serum total bilirubin.

Conditions

  • Liver Dysfunction
  • Hepatectomy
  • Bilirubinaemia
  • Jaundice

Interventions

DRUG

Dexamethasone

Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Hui-Chuan Sun, MD · Liver Cancer Insitute and Zhongshan Hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-12-31
Completion
2018-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02991339 on ClinicalTrials.gov